Literature DB >> 32504780

SAP interacts with CD28 to inhibit PD-1 signaling in T lymphocytes.

Sabina Sandigursky1, Mark R Philips1, Adam Mor2.   

Abstract

T cell co-stimulation is important for the maintenance of immunologic tolerance. Co-inhibitory receptors including programmed cell death-1 (PD-1) confer peripheral tolerance to prevent autoimmunity. SAP (SH2D1A) is an adaptor molecule that is important in T cell signaling and has been shown to interact with signaling lymphocytic activation molecule (SLAM) family receptors also in the context of self-tolerance. We recently reported that SAP interferes with PD-1 function. In the current study, we investigated the levels of SAP and PD-1 in patients with rheumatoid arthritis (RA) to further understand what role they play in disease activity. We observed increased SAP levels in lymphocytes of RA patients and found that PD-1 levels correlated positively with RA disease activity. Additionally, we found that SAP interacts with CD28 to inhibit T cell signaling in vitro. This work demonstrates a putative molecular mechanism for SAP mediated PD-1 inhibition.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD28; DAS28; PD-1; Rheumatoid arthritis; SAP

Mesh:

Substances:

Year:  2020        PMID: 32504780      PMCID: PMC9278890          DOI: 10.1016/j.clim.2020.108485

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   10.190


  30 in total

1.  Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis.

Authors:  Deepak A Rao; Michael F Gurish; Jennifer L Marshall; Kamil Slowikowski; Chamith Y Fonseka; Yanyan Liu; Laura T Donlin; Lauren A Henderson; Kevin Wei; Fumitaka Mizoguchi; Nikola C Teslovich; Michael E Weinblatt; Elena M Massarotti; Jonathan S Coblyn; Simon M Helfgott; Yvonne C Lee; Derrick J Todd; Vivian P Bykerk; Susan M Goodman; Alessandra B Pernis; Lionel B Ivashkiv; Elizabeth W Karlson; Peter A Nigrovic; Andrew Filer; Christopher D Buckley; James A Lederer; Soumya Raychaudhuri; Michael B Brenner
Journal:  Nature       Date:  2017-02-01       Impact factor: 49.962

2.  PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation.

Authors:  Alessandra Petrelli; Gerdien Mijnheer; David P Hoytema van Konijnenburg; Maria M van der Wal; Barbara Giovannone; Enric Mocholi; Nadia Vazirpanah; Jasper C Broen; Dirkjan Hijnen; Bas Oldenburg; Paul J Coffer; Sebastian J Vastert; Berent J Prakken; Eric Spierings; Aridaman Pandit; Michal Mokry; Femke van Wijk
Journal:  J Clin Invest       Date:  2018-08-02       Impact factor: 14.808

3.  The effect of methotrexate (MTX) on expression of signalling lymphocytic activation molecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine production.

Authors:  Y Morita; T Fukazawa; M Hirashima; K Kaga; M Kusaoi; T Morita; S Touyama; K Morita; Y Takasaki; H Hashimoto
Journal:  Scand J Rheumatol       Date:  2006 Jul-Aug       Impact factor: 3.641

4.  CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A.

Authors:  L M Shlapatska; S V Mikhalap; A G Berdova; O M Zelensky; T J Yun; K E Nichols; E A Clark; S P Sidorenko
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

5.  Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor.

Authors:  Michael Peled; Anna S Tocheva; Sabina Sandigursky; Shruti Nayak; Elliot A Philips; Kim E Nichols; Marianne Strazza; Inbar Azoulay-Alfaguter; Manor Askenazi; Benjamin G Neel; Adam J Pelzek; Beatrix Ueberheide; Adam Mor
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-27       Impact factor: 11.205

6.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

7.  Failure to confirm association between PDCD1 polymorphisms and rheumatoid arthritis in a Japanese population.

Authors:  Takuji Iwamoto; Katsunori Ikari; Eisuke Inoue; Yoshiaki Toyama; Masako Hara; Hisashi Yamanaka; Taisuke Tomatsu; Shigeki Momohara; Naoyuki Kamatani
Journal:  J Hum Genet       Date:  2007-04-28       Impact factor: 3.172

8.  Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1.

Authors:  D Bommarito; C Hall; L S Taams; V M Corrigall
Journal:  Clin Exp Immunol       Date:  2017-04-03       Impact factor: 4.330

9.  Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy.

Authors:  Javier Celis-Gutierrez; Peter Blattmann; Yunhao Zhai; Nicolas Jarmuzynski; Kilian Ruminski; Claude Grégoire; Youcef Ounoughene; Frédéric Fiore; Ruedi Aebersold; Romain Roncagalli; Matthias Gstaiger; Bernard Malissen
Journal:  Cell Rep       Date:  2019-06-11       Impact factor: 9.423

10.  Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis.

Authors:  Jimmy Z Liu; Johannes Roksund Hov; Trine Folseraas; Eva Ellinghaus; Simon M Rushbrook; Nadezhda T Doncheva; Ole A Andreassen; Rinse K Weersma; Tobias J Weismüller; Bertus Eksteen; Pietro Invernizzi; Gideon M Hirschfield; Daniel Nils Gotthardt; Albert Pares; David Ellinghaus; Tejas Shah; Brian D Juran; Piotr Milkiewicz; Christian Rust; Christoph Schramm; Tobias Müller; Brijesh Srivastava; Georgios Dalekos; Markus M Nöthen; Stefan Herms; Juliane Winkelmann; Mitja Mitrovic; Felix Braun; Cyriel Y Ponsioen; Peter J P Croucher; Martina Sterneck; Andreas Teufel; Andrew L Mason; Janna Saarela; Virpi Leppa; Ruslan Dorfman; Domenico Alvaro; Annarosa Floreani; Suna Onengut-Gumuscu; Stephen S Rich; Wesley K Thompson; Andrew J Schork; Sigrid Næss; Ingo Thomsen; Gabriele Mayr; Inke R König; Kristian Hveem; Isabelle Cleynen; Javier Gutierrez-Achury; Isis Ricaño-Ponce; David van Heel; Einar Björnsson; Richard N Sandford; Peter R Durie; Espen Melum; Morten H Vatn; Mark S Silverberg; Richard H Duerr; Leonid Padyukov; Stephan Brand; Miquel Sans; Vito Annese; Jean-Paul Achkar; Kirsten Muri Boberg; Hanns-Ulrich Marschall; Olivier Chazouillères; Christopher L Bowlus; Cisca Wijmenga; Erik Schrumpf; Severine Vermeire; Mario Albrecht; John D Rioux; Graeme Alexander; Annika Bergquist; Judy Cho; Stefan Schreiber; Michael P Manns; Martti Färkkilä; Anders M Dale; Roger W Chapman; Konstantinos N Lazaridis; Andre Franke; Carl A Anderson; Tom H Karlsen
Journal:  Nat Genet       Date:  2013-04-21       Impact factor: 38.330

View more
  3 in total

1.  SHP2 Targets ITK Downstream of PD-1 to Inhibit T Cell Function.

Authors:  Marianne Strazza; Kieran Adam; Shalom Lerrer; Johanna Straube; Sabina Sandigursky; Beatrix Ueberheide; Adam Mor
Journal:  Inflammation       Date:  2021-02-24       Impact factor: 4.657

Review 2.  SLAM Associated Protein Signaling in T Cells: Tilting the Balance Toward Autoimmunity.

Authors:  Yevgeniya Gartshteyn; Anca D Askanase; Adam Mor
Journal:  Front Immunol       Date:  2021-04-16       Impact factor: 7.561

Review 3.  Diacylglycerol Kinase alpha in X Linked Lymphoproliferative Disease Type 1.

Authors:  Suresh Velnati; Sara Centonze; Federico Girivetto; Gianluca Baldanzi
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.